BMO Capital Markets Upgrades Precision BioSciences (NASDAQ:DTIL) to Outperform

Precision BioSciences (NASDAQ:DTIL) was upgraded by equities researchers at BMO Capital Markets from a “market perform” rating to an “outperform” rating in a note issued to investors on Friday, MarketBeat Ratings reports. The firm currently has a $34.00 target price on the stock.

Precision BioSciences Stock Performance

NASDAQ:DTIL opened at $4.50 on Friday. The stock has a 50-day moving average price of $6.15 and a 200 day moving average price of $8.30. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.34. Precision BioSciences has a 12-month low of $3.61 and a 12-month high of $19.43. The stock has a market capitalization of $34.52 million, a P/E ratio of 75.01 and a beta of 1.51.

Institutional Trading of Precision BioSciences

An institutional investor recently raised its position in Precision BioSciences stock. Janus Henderson Group PLC grew its position in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 10.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 702,069 shares of the company’s stock after purchasing an additional 68,943 shares during the period. Janus Henderson Group PLC owned approximately 9.15% of Precision BioSciences worth $6,322,000 at the end of the most recent reporting period. 37.99% of the stock is owned by institutional investors and hedge funds.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.